肠出血性大肠埃希菌感染与溶血性尿毒症综合征
被引量：1
摘要
近年来,各种感染性疾病逐渐成为医学界研究的热点,与之相关的各种细菌、病毒及其继发疾病的研究也更加深入。本文选译自《最新医学》2005年第60卷第2期“感染症の?症”专辑,选文15篇,就感染性疾病的各种继发症作系统阐述,内容全面、新颖,有较高的参考价值。全文由哈尔滨医科大学附属二院姚桢教授审校。
出处
《日本医学介绍》
2006年第4期152-153,共2页
Progress in Japanese Medicine
同被引文献24
-
1樊曦涌,姚勇,杨霁云.抗生素在溶血尿毒综合征中应用的研究进展[J].中国实用儿科杂志,2006,21(8):635-637. 被引量：1
-
2Seto EY, Soller JA, Colford JM Jr. Strategies to reduce person - to - person transmission during widespread Escherichia coli O157 :H7 outbreak. Emerg Infect Dis,2007,13 ( 6 ) : 860 - 866.
-
3Noris M, Remuzzi G, Hemolytic Uremic Syndrome. J Am Soc Nephrol, 2005,16(5 ) : 1035 - 1050.
-
4MacConnachie AA, Todd WT. Potential therapeutic agents for the prevention and treatment of haemolytic uraemic syndrome in shiga toxin producing Escherichia coli infection. Curr Opin Infect Dis ,2004 ,17(5) :479 -482.
-
5Trachtman H,Cnaan A, Christen E ,et al. Effect of an oral Shiga toxin -binding agent on diarrhea- associated hemolytic uremic syndrome in children : a randomized controlled trial. JAMA, 2003, 290 ( 10 ) :1337 - 1344.
-
6Pinyon RA,Paton JC, Paton AW, et al. Refinement of a therapeutic Shiga toxin - binding probiotic for human trials. J Infect Dis, 2004, 189(9) :1547 - 1555.
-
7Neri P, Nagano SI, Yokoyama S, et al. Neutralizing activity of polyvalent Gb3, Gb2 and galacto - trehalose models against Shiga toxins. Microbiol Immunol,2007,51 (6) :581 - 592.
-
8Kuribayashi T, Seita T, Fukuyama M, et al. Neutralizing activity of bovine colostral antibody against verotoxin derived from enterohemorrhagic Escherichia coli O157 :H7 in mice. J Infect Chemother,2006, 12 (5) :251 - 256.
-
9Wen SX, Teel LD, Judge NA, et al. A plant - based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proc Natl Acad Sci U S A,2006, 103(18) :7082 -7087.
-
10Ahmed A, Li J, Shiloach Y, et al. Safety and immunogenicity of Escherichia coli 0157 O - specific polysaccharide conjugate vaccine in 2 -5 -year - old children. J Infect Dis,2006, 193(4) : 515 - 521.
-
1卢林耿,卫国荣,周晓明,张幼辰,俞顺章.PCR法检测大肠杆菌O_(157)志贺样毒素[J].上海医科大学学报,1999,26(6):451-452. 被引量：4
-
2陈怀青.大肠杆菌Vero毒素研究进展[J].国外医学（微生物学分册）,1994,17(6):258-260. 被引量：2
-
3赵红.大肠杆菌O157:H7致病因子及其保护性免疫研究现状[J].微生物学免疫学进展,2002,30(2):77-81.
-
4杨建国,戴时新.一起金黄色葡萄球菌食物中毒的临床分析[J].中国社区医师（医学专业）,2005,7(16):94-94. 被引量：3
-
5秦恩强,赵敏.新型肠出血性大肠杆菌感染防治[J].传染病信息,2011,24(3). 被引量：3
-
6余传霖.肠出血性大肠埃希菌产生的Vero毒素[J].国外医学（微生物学分册）,1994,17(3):124-125. 被引量：3
-
7周志江,黄上媛,郑明光,汪力亚,王丽,李景云,赖平安.猪和鸡源性产vero毒素大肠埃希氏菌的检测[J].中国兽医科技,1998,28(12):35-36.
-
8徐建国.第三讲 O157∶H7大肠杆菌和肠出血性大肠杆菌[J].疾病监测,1997,12(7):278-279.
-
9李景学,崔树玉,刘齐家.肠出血性大肠杆菌O157:H7的实验室诊断[J].国外医学（微生物学分册）,1993,16(2):76-79. 被引量：13
-
10Smith H R,于泉.产Vero毒素大肠杆菌[J].微生物学免疫学进展,1989,17(1):61-67.
